‘Astounding amount’ of vasculitis trials opens mixed bag of ‘exciting,’ ‘frustrating’ data

SCOTTSDALE, AZ, — Recent efforts in vasculitis research have seen both “exciting” and “frustrating” results, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.
“Vasculitis is a really exciting field to be in,” Adam Brown, MD, from the department of rheumatologic and immunologic disease at Cleveland Clinic, told attendees. “There is really an astounding amount of trials going on in a very rare disease.”
These trials are focused primarily on giant cell arteritis (GCA), anti-neutrophil cytoplasmic

SCOTTSDALE, AZ, — Recent efforts in vasculitis research have seen both “exciting” and “frustrating” results, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.
“Vasculitis is a really exciting field to be in,” Adam Brown, MD, from the department of rheumatologic and immunologic disease at Cleveland Clinic, told attendees. “There is really an astounding amount of trials going on in a very rare disease.”
These trials are focused primarily on giant cell arteritis (GCA), anti-neutrophil cytoplasmic